The U.S. Food and Drug Administration granted the application priority review status, accelerating the timeline for a potential market entry. The agency has set a target action date for November, which could provide a new therapeutic option for those grappling with the debilitating symptoms of the disease.
In section Market Quotes
Regeneron Advances Cemdisiran for Myasthenia Gravis Treatment
Regeneron Pharmaceuticals has secured regulatory traction for cemdisiran, as both the FDA and European Medicines Agency accepted applications to treat adults suffering from generalized myasthenia gravis. The drug candidate, developed in partnership with Alnylam Pharmaceuticals, targets patients who are anti-acetylcholine receptor antibody-positive, marking a significant step in managing the chronic autoimmune condition.
Across the Atlantic, the European Medicines Agency is conducting its own review of the data. The Tarrytown-based biotechnology firm anticipates a final decision from the European Commission during the second half of 2027. The drug originates from a licensing agreement between Regeneron and Alnylam, aiming to address the specific needs of patients with the anti-acetylcholine receptor antibody-positive form of the illness.
Comments (0)
No comments yet. Be the first!